Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-660671

ABSTRACT

Cardiogenic shock is caused by dysfunction of the cardiac pump,resulting in multiple or-gan failure and metabolic disturbances. Because of its rapid onset,various manifestations,rapid progress and high mortality rate,it becomes one of the critical diseases in pediatrics. Early diagnosis and active treatment is the key to improve prognosis. The application of hemodynamic monitoring and mechanical circulatory assist devices play an increasingly important role in the treatment of cardiogenic shock in children.

2.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-662755

ABSTRACT

Cardiogenic shock is caused by dysfunction of the cardiac pump,resulting in multiple or-gan failure and metabolic disturbances. Because of its rapid onset,various manifestations,rapid progress and high mortality rate,it becomes one of the critical diseases in pediatrics. Early diagnosis and active treatment is the key to improve prognosis. The application of hemodynamic monitoring and mechanical circulatory assist devices play an increasingly important role in the treatment of cardiogenic shock in children.

3.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-814934

ABSTRACT

OBJECTIVE@#To compare the changes in muscle enzyme between children with myocarditis and Duchene/Becker muscular dystrophy (DMD/BMD), and to seek the explanations for variation.
@*METHODS@#The retrospective analysis for 83 myocarditis children (myocarditis group) and 69 DMD/BMD children (DMD/BMD group), who were collected from Department of Pediatric of Shengjing Hospital affiliated to China Medical University since January 2008 to May 2015, was carried out. At the same time, 24 healthy children from the Department of Pediatric Development served as a control group. The examination indexes included creatine kinase (CK), creatine kinase-isoenzyme MB (CK-MB), creatine kinase isoenzyme MB mass (CK-MB mass), cardiac troponin I (cTnI) and high-sensitive-cTnT (hs-cTnT).
@*RESULTS@#1) In the myocarditis group, the CK increased from 100 to 1 000 U/L, reached a peak after 5 days, which lasted for a week and then dropped to the normal; the CK-MB reached a peak after 5 to 7 days and dropped to the normal a month later; the CK-MB mass reached a peak on the first day and dropped to the normal after 3 weeks; the cTn reached to a peak after 5 days and dropped to the normal after about 17 days; hs-cTnT reached to a peak on the first day and dropped to the normal after about 19 days. 2) In the DMD/BMD group, the CK increased significantly and 27 cases had a CK value of more than 10 000 U/L. After the treatment for 1 to 2 weeks, their enzyme rose again after a slight drop. In terms of cTnI, 6 cases showed a moderate increase, 5 of them couldn't drop to the normal level until more than 3 weeks later; the hs-cTnT increased in the 45 cases, which lasted for more than 3 weeks in the 31 cases of them and showed a tendency of persisting increase.
@*CONCLUSION@#The cTnI and hs-cTnT rise significantly and possess wider observation window than CK and CK-MB mass in myocarditis children, with more sensitive and specific changes. The myocardial damage can occur before myasthenia and keep this trend for a long time in the DMD/BMD children. The trend of cTnI change in myocarditis children is similar to hs-cTnT, while hs-cTnT in DMD/BMD children is more sensitive than cTnI.


Subject(s)
Child , Female , Humans , Male , Biomarkers , China , Creatine Kinase , Blood , Metabolism , Creatine Kinase, MB Form , Blood , Metabolism , Muscle Weakness , Muscular Dystrophy, Duchenne , Therapeutics , Myocarditis , Therapeutics , Retrospective Studies , Time Factors , Troponin I , Blood , Metabolism , Troponin T , Blood , Metabolism
4.
Arthritis Rheum ; 56(12): 4174-81, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18050248

ABSTRACT

OBJECTIVE: Receptor for advanced glycation end products (RAGE) serves as a pattern recognition receptor for several endogenous ligands that are potent inducers of inflammation. By activating endothelial cells and leukocytes, RAGE augments recruitment of leukocytes to sites of inflammation, which is a key process, especially in vasculitis. Soluble RAGE (sRAGE) acts as a naturally occurring inhibitor of RAGE by neutralizing proinflammatory ligands, e.g., S100A12. This neutrophil-derived protein has been reported to be associated with Kawasaki disease (KD) and to provoke proinflammatory responses. The aim of this study was to investigate circulating sRAGE in an acute inflammatory disorder and to compare these data directly with concentrations of the proinflammatory RAGE ligand S100A12. METHODS: Serum concentrations of sRAGE and S100A12 were analyzed by specific enzyme-linked immunosorbent assays in 50 children with KD, and additionally in 39 patients with juvenile idiopathic arthritis (JIA). In 28 of the patients with KD, levels were analyzed longitudinally over the course of the disease. RESULTS: Patients with KD and those with systemic-onset JIA had decreased levels of sRAGE during active disease, especially those patients with KD who were more severely affected and not responding to treatment. In addition, the level of sRAGE correlated negatively with the level of proinflammatory S100A12. After intravenous immunoglobulin (IVIG) therapy in patients with KD, the S100A12:sRAGE ratio was significantly different between responders and nonresponders. CONCLUSION: Inverse regulation of both sRAGE and its proinflammatory ligand S100A12 seems to be a relevant molecular mechanism promoting systemic inflammation. Calculating the S100A12:sRAGE ratio might help to detect patients with KD who are at risk of being unresponsive to IVIG therapy.


Subject(s)
Mucocutaneous Lymph Node Syndrome/blood , Receptors, Immunologic/blood , S100 Proteins/blood , Arthritis, Juvenile/blood , Biomarkers/blood , Case-Control Studies , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Infant , Longitudinal Studies , Male , Mucocutaneous Lymph Node Syndrome/drug therapy , Receptor for Advanced Glycation End Products , S100A12 Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...